{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:08:36Z","timestamp":1787238516352,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03034-6","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T03:02:15Z","timestamp":1725246135000},"page":"1349-1362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice"],"prefix":"10.1007","volume":"57","author":[{"given":"Siqian","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shundong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-4885","authenticated-orcid":false,"given":"Miao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"issue":"2","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/ng1153","volume":"34","author":"B Zhang","year":"2003","unstructured":"Zhang B, Cunningham MA, Nichols WC et al (2003) Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 34(2):220\u2013225. https:\/\/doi.org\/10.1038\/ng1153","journal-title":"Nat Genet"},{"issue":"1","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0092-8674(00)81146-0","volume":"93","author":"WC Nichols","year":"1998","unstructured":"Nichols WC, Seligsohn U, Zivelin A et al (1998) Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 93(1):61\u201370. https:\/\/doi.org\/10.1016\/s0092-8674(00)81146-0","journal-title":"Cell"},{"issue":"6","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1055\/s-0033-1349223","volume":"39","author":"C Zheng","year":"2013","unstructured":"Zheng C, Zhang B (2013) Combined deficiency of coagulation factors V and VIII: an update. Semin Thromb Hemost 39(6):613\u2013620. https:\/\/doi.org\/10.1055\/s-0033-1349223","journal-title":"Semin Thromb Hemost"},{"key":"3034_CR4","doi-asserted-by":"publisher","first-page":"101029","DOI":"10.1016\/j.blre.2022.101029","volume":"59","author":"A Dorgalaleh","year":"2023","unstructured":"Dorgalaleh A, Bahraini M, Shams M et al (2023) Molecular basis of rare congenital bleeding disorders. Blood Rev 59:101029. https:\/\/doi.org\/10.1016\/j.blre.2022.101029","journal-title":"Blood Rev"},{"issue":"5","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2005-09-3620","volume":"107","author":"B Zhang","year":"2006","unstructured":"Zhang B, McGee B, Yamaoka JS et al (2006) Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 107(5):1903\u20131907. https:\/\/doi.org\/10.1182\/blood-2005-09-3620","journal-title":"Blood"},{"issue":"12","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1182\/blood-2007-10-113951","volume":"111","author":"B Zhang","year":"2008","unstructured":"Zhang B, Spreafico M, Zheng C et al (2008) Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood 111(12):5592\u20135600. https:\/\/doi.org\/10.1182\/blood-2007-10-113951","journal-title":"Blood"},{"issue":"1","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2141.2008.07559.x","volume":"145","author":"B Zhang","year":"2009","unstructured":"Zhang B (2009) Recent developments in the understanding of the combined deficiency of FV and FVIII. Br J Haematol 145(1):15\u201323. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07559.x","journal-title":"Br J Haematol"},{"issue":"11","key":"3034_CR8","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/bloodadvances.2021006214","volume":"6","author":"M Jiang","year":"2022","unstructured":"Jiang M, Yang F, Jiang Y et al (2022) Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C. Blood Adv 6(11):3304\u20133314. https:\/\/doi.org\/10.1182\/bloodadvances.2021006214","journal-title":"Blood Adv"},{"issue":"12","key":"3034_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.2023020005","volume":"142","author":"M Jiang","year":"2023","unstructured":"Jiang M, Yang F, Jiang Y et al (2023) Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models. Blood 142(12):1071\u20131081. https:\/\/doi.org\/10.1182\/blood.2023020005","journal-title":"Blood"},{"issue":"4","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/pr.120.019554","volume":"72","author":"AM Yu","year":"2020","unstructured":"Yu AM, Choi YH, Tu MJ (2020) RNA Drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol Rev 72(4):862\u2013898. https:\/\/doi.org\/10.1124\/pr.120.019554","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3034_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pharmrev.123.000815","volume":"76","author":"A Gogate","year":"2023","unstructured":"Gogate A, Belcourt J, Shah M et al (2023) Targeting the liver with nucleic acid therapeutics for the treatment of systemic diseases of liver origin. Pharmacol Rev 76(1):49\u201389. https:\/\/doi.org\/10.1124\/pharmrev.123.000815","journal-title":"Pharmacol Rev"},{"issue":"5","key":"3034_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11883-022-01007-9","volume":"24","author":"N Bejar","year":"2022","unstructured":"Bejar N, Tat TT, Kiss DL (2022) RNA therapeutics: the next generation of drugs for cardiovascular diseases. Curr Atheroscler Rep 24(5):307\u2013321. https:\/\/doi.org\/10.1007\/s11883-022-01007-9","journal-title":"Curr Atheroscler Rep"},{"issue":"7713","key":"3034_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","volume":"559","author":"SM Haag","year":"2018","unstructured":"Haag SM, Gulen MF, Reymond L et al (2018) Targeting STING with covalent small-molecule inhibitors. Nature 559(7713):269\u2013273. https:\/\/doi.org\/10.1038\/s41586-018-0287-8","journal-title":"Nature"},{"issue":"5","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L et al (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21(5):492\u2013497. https:\/\/doi.org\/10.1038\/nm.3847","journal-title":"Nat Med"},{"key":"3034_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-4939-3378-5_15","volume":"1402","author":"H Hatakeyama","year":"2016","unstructured":"Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK (2016) Assessment of in vivo siRNA delivery in cancer mouse models. Methods Mol Biol 1402:189\u2013197. https:\/\/doi.org\/10.1007\/978-1-4939-3378-5_15","journal-title":"Methods Mol Biol"},{"issue":"20","key":"3034_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gni178","volume":"33","author":"C Chen","year":"2005","unstructured":"Chen C, Ridzon DA, Broomer AJ et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33(20):e179. https:\/\/doi.org\/10.1093\/nar\/gni178","journal-title":"Nucleic Acids Res"},{"issue":"9_suppl","key":"3034_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1076029618790696","volume":"24","author":"Q Wang","year":"2018","unstructured":"Wang Q, Cao L, Sheng G et al (2018) Application of high-throughput sequencing in the diagnosis of inherited thrombocytopenia. Clin Appl Thromb Hemost 24(9_suppl):94\u2013103. https:\/\/doi.org\/10.1177\/1076029618790696","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"3034_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nbt1404","volume":"26","author":"H Tafer","year":"2008","unstructured":"Tafer H, Ameres SL, Obernosterer G, Gebeshuber CA, Schroeder R, Martinez J, Hofacker IL (2008) The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 26(5):578\u2013583. https:\/\/doi.org\/10.1038\/nbt1404","journal-title":"Nat Biotechnol"},{"issue":"9859","key":"3034_CR19","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(12)61728-0","journal-title":"Lancet"},{"issue":"9","key":"3034_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe AM, Raskob GE (2016) Global burden of thrombosis: epidemiologic aspects. Circ Res 118(9):1340\u20131347. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306841","journal-title":"Circ Res"},{"key":"3034_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.thromres.2022.04.013","volume":"214","author":"KE Kluge","year":"2022","unstructured":"Kluge KE, Seljeflot I, Arnesen H, Jensen T, Halvorsen S, Helseth R (2022) Coagulation factors XI and XII as possible targets for anticoagulant therapy. Thromb Res 214:53\u201362. https:\/\/doi.org\/10.1016\/j.thromres.2022.04.013","journal-title":"Thromb Res"},{"issue":"25","key":"3034_CR22","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1182\/blood-2010-04-278325","volume":"116","author":"C Zheng","year":"2010","unstructured":"Zheng C, Liu HH, Yuan S, Zhou J, Zhang B (2010) Molecular basis of LMAN1 in coordinating LMAN1-MCFD2 cargo receptor formation and ER-to-Golgi transport of FV\/FVIII. Blood 116(25):5698\u20135706. https:\/\/doi.org\/10.1182\/blood-2010-04-278325","journal-title":"Blood"},{"issue":"7","key":"3034_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109144","volume":"35","author":"A Ordonez","year":"2021","unstructured":"Ordonez A, Harding HP, Marciniak SJ, Ron D (2021) Cargo receptor-assisted endoplasmic reticulum export of pathogenic alpha1-antitrypsin polymers. Cell Rep 35(7):109144. https:\/\/doi.org\/10.1016\/j.celrep.2021.109144","journal-title":"Cell Rep"},{"issue":"6","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP (2019) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18(6):421\u2013446. https:\/\/doi.org\/10.1038\/s41573-019-0017-4","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ (2020) Therapeutic siRNA: state of the art. Signal Transduct Target Ther 5(1):101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3034_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discovery 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3034_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"issue":"9911","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s0140-6736(13)61914-5","volume":"383","author":"K Fitzgerald","year":"2014","unstructured":"Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S et al (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet (London, England) 383(9911):60\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(13)61914-5","journal-title":"Lancet (London, England)"},{"issue":"1","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376(1):41\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1609243","journal-title":"N Engl J Med"},{"issue":"4","key":"3034_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","volume":"79","author":"E Gane","year":"2023","unstructured":"Gane E, Lim YS, Kim JB et al (2023) Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol 79(4):924\u2013932. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.023","journal-title":"J Hepatol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03034-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:04:13Z","timestamp":1734091453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03034-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03034-6","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"11 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}